Brief: Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
17/12/2020 12:14
Dec 17 (Reuters) - Sigilon Therapeutics, Inc. SGTX.O :
* SIGILON THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR
SIG-005 FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE I
* SIGILON THERAPEUTICS, INC. - ANTICIPATE INITIATING A PHASE
1/2
CLINICAL TRIAL IN PATIENTS WITH MPS-1 IN SECOND HALF OF 2021
Source text for Eikon: ID:nGNX3LwvMH
Further company coverage: SGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sigilon Therapeutics
See all newsSigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Sigilon Therapeutics Inc expected to post a loss of $4.71 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
Sigilon jumps on Eli Lilly's buyout deal to expand diabetes treatments
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx